Silver Book Fact

A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.

Reference

Title
Memantine in Moderate-to-Severe Alzheimer’s Disease
Publication
N Eng J Med
Publication Date
2003
Authors
Reisberg B, Doody R, Stoffler A, Schmitt F, et al
Volume & Issue
Volume 348, Issue 14
Pages
1333-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…  
  • Impact of Slowed Progression on Severe Stage, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • Based on rates of admission in 1998, delaying admission of Alzheimer’s patients to nursing homes by 1 month could save as much as $1.12 billion a year.  
  • The U.S. Food and Drug Administration has approved five drugs that temporarily improve Alzheimer’s disease symptoms.